Article Publish Status: FREE
Abstract Title:

Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial.

Abstract Source:

Nutrients. 2019 Mar 16 ;11(3). Epub 2019 Mar 16. PMID: 30884808

Abstract Author(s):

Rebeca Quirós-Fernández, Bricia López-Plaza, Laura M Bermejo, Samara Palma-Milla, Carmen Gómez-Candela

Article Affiliation:

Rebeca Quirós-Fernández


Hydroxytyrosol (HT) and Punicalagin (PC) exert cardioprotective and anti-atherosclerotic effects. This study evaluates the effect of oral supplementation with HT and PC (SAx) on early atherosclerosis markers in middle-aged, seemingly healthy adults. A randomized, double-blinded, placebo-controlled, crossover trial was performed for 20 weeks. There were two treatment sequences (Placebo/SAx, n = 41; SAx/Placebo, n = 43) for which the intervention periods (Placebo and SAx) were 8 weeks long, followed by a 4-week wash out period. The supplement was composed of 9.9 mg of HT and 195 mg of PC, and the placebo was composed of maltodextrin. SAx increased endothelial function (Flow-mediated dilatation [FMD]: 2.36%;<0.001) in the endothelial dysfunction subgroup compared to the placebo (2.36± 3.9 vs. 0.76 ± 3.5%,<0.05). SAx also reduced oxLDL by -28.74 ng/mL (<0.05) in subjects with higher levels of oxLDL, which was an improvement compared with the placebo (-28.74± 40.2 vs. 25.64 ± 93.8 ng/mL,<0.001). The prehypertension and hypertension subgroups exhibited decreased systolic (-15.75± 9.9 mmHg;<0.001) and diastolic (-6.36± 8.7 mmHg;<0.001) blood pressure after SAx consumption. Moreover, the systolic prehypertension and hypertension subgroups presented significant differences in systolic blood pressure compared to the placebo (-15.75± 9.9 vs. -2.67 ± 12.0 mmHg,<0.05). In conclusion, the supplement exerted anti-atherosclerotic effects by improving endothelial function, blood pressure, and levels of circulating oxLDL, especially for persons in whom these parameters were altered.

Study Type : Human Study

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.